The confirmation of Merck & Co. Inc.'s impending acquisition of Cubist Pharmaceuticals Inc. in early December 2014 has provided Merck with access to the market for developing novel antibiotics and combating superbugs. The deal is the latest indication that major pharmaceutical companies could be focusing their attention back to antibiotic development following decades of low investment.